Abstract Library

#4474 Follow-up 68Ga-DOTATATE PET/CT post resection of small bowel neuroendocrine neoplasia

Introduction: Surgery remains the mainstay of treatment for resectable neuroendocrine neoplasms (NENs). Post resection, guidelines suggest a risk-based approach to surveillance, with 3-6 monthly imaging based on tumour biology. However, there is a paucity of data regarding the timing of surveillance imaging for resected well-differentiated NEN.

Conference:

Presenting Author:

Authors: Sabahi Z, Chan D, Darbhamulla S, Mok C, Samra J,

Keywords: Neuroendocrine, 68Ga-DOTATATE PET/CT, Small bowel,

#4363 61Cu-NODAGA-LM3 for the detection of neuroendocrine tumours: Preliminary results of the COPPER PET in NET trial, a randomised, crossover, readers blind, phase I/II non-inferiority study

Introduction: Currently approved PET tracers, Gallium-68 or Copper-64 labelled somatostatin receptor (SST) agonists (NETSPOT®, SOMAKIT® and Detecnet™), for imaging well-differentiated gastroenteropancreatic and bronchopulmonary neuroendocrine tumours (NET) have limitations. Radiolabelled SST antagonists offer superior imaging properties over agonists, and the combination with Copper-61, an unexplored PET isotope with a 3.33-hour half-life and favourable production characteristics, could be promising.

Conference:

Presenting Author: Nicolas G

Authors: Nicolas G, Chirindel A, Kaul F, Rommers N, Johayem A,

Keywords: Somatostatin Receptor PET/CT, Well-differentiated NEN, gastroenteropancreatic NET, bronchopulmonary NET, randomised controlled clinical trial, somatostatin receptor antagonist,

#3817 Mid-treatment response to 177Lu-DOTATATE – A possible estimate for final outcome in patients with neuroendocrine neoplasms

Introduction: Patients with advanced or unresectable neuroendocrine neoplasm (NENs) have limited systemic treatment modalities. Among the patients receiving peptide receptor radionuclide therapy (PRRT) treatment with 177Lu-DOTATATE, a subset will require further chemotherapy in later stages. Hence, limiting radiation exposure is of paramount importance. However, there are no mid-term predictive factors for response to PRRT.

Conference:

Presenting Author:

Authors: Halperin R, Tirosh A,

Keywords: PRRT, predictive factor, response, peptide receptor radionuclide therapy, efficacy, well-differentiated,

#3456 Clinicopathological characteristics and treatment options of the new grade 3 neuroendocrine tumor subgroup (NETs G3)

Introduction: NET G3 is a new subgroup of well-differentiated NENs. The impact of morphological characteristics on clinical course and treatment tactics is still questionable.

Conference:

Presenting Author: Evdokimova E

Authors: Evdokimova E, Artamonova E, Chemeris G, Yemelyanova G, Markovich A,

Keywords: NET G3, SSTR, ki67, somatostatin analogues,

#3171 Prognostic and diagnostic value of serum 5-HIAA in well-differentiated neuroendocrine neoplasms

Introduction: There are only few studies on the diagnostic value of serum 5HIAA as compared to the 24-hours urinary sampling method and a lack of evidence on the prognostic significance of its serum levels, as well as the markers' ability to predict changes in disease status.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Wedin M

Authors: Wedin M, Mehta S, Angerås-Kraftling J, Wallin G, Daskalakis K,

Keywords: biomarker, serum 5HIAA, well-differentiated NEN,